Send to

Choose Destination
See comment in PubMed Commons below
Dermatol Surg. 2002 Jan;28(1):21-5.

The utilization of a new yellow light laser (578 nm) for the treatment of class I red telangiectasia of the lower extremities.

Author information

  • 1Department of Dermatology, Cornell-Weill Medical College, New York, New York, USA.



A dual-wavelength approach is necessary in order to achieve consistent results when utilizing lasers and intense pulsed light sources to treat red and blue lower extremity vessels. In this regard, short-wavelength technologies (500-800 nm) may be employed to treat red telangiectasia of less than 2 mm on the lower extremities.


To demonstrate a new yellow light laser utilizing a copper bromide medium and its potential efficacy in the treatment of red lower extremity telangiectasia of less than 2 mm.


Forty-six women (mean age 37 years) were treated in two private practice settings with a 578 nm yellow light laser with a circulating cooling window (1-4 degrees C). Class I red telangiectases of the thighs 1.5 mm or less in diameter were considered for treatment. Patients were treated with up to three treatments at 6-week intervals on a 5 cm2 surgical area of vessels utilizing a fluence of 50-55 J/cm2. Results were analyzed by macrophotographic imaging, double-blinded observer evaluation/optical chromatography, and a patient evaluation scale.


An average of 1.7 patient treatment sessions produced significant clearing of 75-100% in 71.8% of patients. The mean erythema index showed significant lightening (51-65a+) in the study population. Finally, 76.1% of patients reported great satisfaction with the results of their treatment session.


A new 578 nm copper bromide (CuBr) yellow light laser produces excellent results in eradicating red telangiectases of the lower extremities that are less than 2 mm in diameter.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Lippincott Williams & Wilkins
    Loading ...
    Write to the Help Desk